Literature DB >> 22835581

Liver test results do not identify liver disease in adults with α(1)-antitrypsin deficiency.

Virginia C Clark1, Renumathy Dhanasekaran, Mark Brantly, Farshid Rouhani, Pamela Schreck, David R Nelson.   

Abstract

BACKGROUND & AIMS: Liver disease is a significant cause of death among adults with α(1)-antitrypsin (A-AT) deficiency. Age and male sex are reported risk factors for liver disease. In the absence of adequate risk stratification, current recommendations are to intermittently test A-AT-deficient adults for liver function. We evaluated this recommendation in a large group of adults with A-AT deficiency to determine the prevalence of increased levels of alanine aminotransferase (ALT) and identify risk factors for liver disease.
METHODS: We used the Alpha-1 Foundation DNA and Tissue Bank to identify a cross section of A-AT-deficient adults (n = 647) with and without liver disease; individuals without A-AT deficiency were used as controls (n = 152). Results from ALT tests were compared between groups.
RESULTS: The prevalence of liver disease among individuals with A-AT deficiency was 7.9%; an increased level of ALT was observed in 7.8% of A-AT-deficient individuals, which did not differ significantly from controls. Mean levels of ALT fell within normal range for all groups. An increased level of ALT identified patients with liver disease with 11.9% sensitivity. The level of only γ-glutamyl transpeptidase was significantly higher in the A-AT-deficient group than in controls (43 vs 30 IU/mL; P < .003). A childhood history of liver disease and male sex were risk factors for adult liver disease in the multivariate analysis.
CONCLUSIONS: An increased level of ALT does not identify adults with A-AT deficiency who have liver disease. Male sex and liver disease during childhood might help identify those at risk.
Copyright © 2012 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22835581      PMCID: PMC3482934          DOI: 10.1016/j.cgh.2012.07.007

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  24 in total

1.  Defining the mechanism of polymerization in the serpinopathies.

Authors:  Ugo I Ekeowa; Joanna Freeke; Elena Miranda; Bibek Gooptu; Matthew F Bush; Juan Pérez; Jeff Teckman; Carol V Robinson; David A Lomas
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-20       Impact factor: 11.205

2.  An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis.

Authors:  Tunda Hidvegi; Michael Ewing; Pamela Hale; Christine Dippold; Caroline Beckett; Carolyn Kemp; Nicholas Maurice; Amitava Mukherjee; Christina Goldbach; Simon Watkins; George Michalopoulos; David H Perlmutter
Journal:  Science       Date:  2010-06-03       Impact factor: 47.728

3.  Natural history and life expectancy in severe alpha1-antitrypsin deficiency, Pi Z.

Authors:  C Larsson
Journal:  Acta Med Scand       Date:  1978

4.  Prospective study of children with alpha 1-antitrypsin deficiency: eight-year-old follow-up.

Authors:  T Sveger
Journal:  J Pediatr       Date:  1984-01       Impact factor: 4.406

5.  Liver disease in alpha1-antitrypsin deficiency detected by screening of 200,000 infants.

Authors:  T Sveger
Journal:  N Engl J Med       Date:  1976-06-10       Impact factor: 91.245

6.  Clinical course and prognosis of never-smokers with severe alpha-1-antitrypsin deficiency (PiZZ).

Authors:  H A Tanash; P M Nilsson; J-A Nilsson; E Piitulainen
Journal:  Thorax       Date:  2008-08-05       Impact factor: 9.139

7.  Updated definitions of healthy ranges for serum alanine aminotransferase levels.

Authors:  Daniele Prati; Emanuela Taioli; Alberto Zanella; Emanuela Della Torre; Sonia Butelli; Emanuela Del Vecchio; Luciana Vianello; Francesco Zanuso; Fulvio Mozzi; Silvano Milani; Dario Conte; Massimo Colombo; Girolamo Sirchia
Journal:  Ann Intern Med       Date:  2002-07-02       Impact factor: 25.391

8.  Risk for liver disease in adults with alpha 1-antitrypsin deficiency.

Authors:  D W Cox; S Smyth
Journal:  Am J Med       Date:  1983-02       Impact factor: 4.965

9.  The liver in 30-year-old individuals with alpha(1)-antitrypsin deficiency.

Authors:  E Bernspång; J Carlson; E Piitulainen
Journal:  Scand J Gastroenterol       Date:  2009       Impact factor: 2.423

10.  Risk of cirrhosis and primary liver cancer in alpha 1-antitrypsin deficiency.

Authors:  S Eriksson; J Carlson; R Velez
Journal:  N Engl J Med       Date:  1986-03-20       Impact factor: 91.245

View more
  12 in total

1.  Antisense oligonucleotide treatment ameliorates alpha-1 antitrypsin-related liver disease in mice.

Authors:  Shuling Guo; Sheri L Booten; Mariam Aghajan; Gene Hung; Chenguang Zhao; Keith Blomenkamp; Danielle Gattis; Andrew Watt; Susan M Freier; Jeffery H Teckman; Michael L McCaleb; Brett P Monia
Journal:  J Clin Invest       Date:  2013-12-20       Impact factor: 14.808

2.  Alpha-1 antitrypsin deficiency and the risk of hepatocellular carcinoma in end-stage liver disease.

Authors:  Clara Antoury; Rocio Lopez; Nizar Zein; James K Stoller; Naim Alkhouri
Journal:  World J Hepatol       Date:  2015-06-08

3.  Low yield and utilization of confirmatory testing in a cohort of patients with liver disease assessed for alpha-1 antitrypsin deficiency.

Authors:  Elliot B Tapper; Vilas R Patwardhan; Michael Curry
Journal:  Dig Dis Sci       Date:  2014-12-23       Impact factor: 3.199

Review 4.  Non-Invasive Assessment and Management of Liver Involvement in Adults With Alpha-1 Antitrypsin Deficiency.

Authors:  Karim Hamesch; Pavel Strnad
Journal:  Chronic Obstr Pulm Dis       Date:  2020-07

5.  Alpha1-Antitrypsin Deficiency: Transition of Care for the Child With AAT Deficiency into Adulthood.

Authors:  Henry C Lin; Nagraj Kasi; J Antonio Quiros
Journal:  Curr Pediatr Rev       Date:  2019

Review 6.  Diagnosis and treatment of lung disease associated with alpha one-antitrypsin deficiency: A position statement from the Thoracic Society of Australia and New Zealand.

Authors:  Jack Dummer; Claudia C Dobler; Mark Holmes; Daniel Chambers; Ian A Yang; Lianne Parkin; Sheree Smith; Peter Wark; Anouk Dev; Sandra Hodge; Eli Dabscheck; Julian Gooi; Sameh Samuel; Steven Knowles; Anne E Holland
Journal:  Respirology       Date:  2020-02-06       Impact factor: 6.424

7.  Liver disease in adults with α1-antitrypsin deficiency.

Authors:  Mattias Mandorfer; Theresa Bucsics; Veronika Hutya; Karin Schmid-Scherzer; Benedikt Schaefer; Heinz Zoller; Arnulf Ferlitsch; Markus Peck-Radosavljevic; Michael Trauner; Peter Ferenci; Meinhard Kneussl; Thomas Reiberger
Journal:  United European Gastroenterol J       Date:  2018-02-28       Impact factor: 4.623

8.  Using antisense technology to develop a novel therapy for α-1 antitrypsin deficient (AATD) liver disease and to model AATD lung disease.

Authors:  Shuling Guo; Sheri L Booten; Andrew Watt; Luis Alvarado; Susan M Freier; Jeffery H Teckman; Michael L McCaleb; Brett P Monia
Journal:  Rare Dis       Date:  2014-03-12

9.  Comparison of non-invasive assessment of liver fibrosis in patients with alpha1-antitrypsin deficiency using magnetic resonance elastography (MRE), acoustic radiation force impulse (ARFI) Quantification, and 2D-shear wave elastography (2D-SWE).

Authors:  Rolf Reiter; Martin Wetzel; Karim Hamesch; Pavel Strnad; Patrick Asbach; Matthias Haas; Britta Siegmund; Christian Trautwein; Bernd Hamm; Dieter Klatt; Jürgen Braun; Ingolf Sack; Heiko Tzschätzsch
Journal:  PLoS One       Date:  2018-04-26       Impact factor: 3.240

10.  Liver disease in adults with severe alpha-1-antitrypsin deficiency.

Authors:  Hanan A Tanash; Eeva Piitulainen
Journal:  J Gastroenterol       Date:  2019-01-24       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.